Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-803 with Haploidentical HCT in High-Risk Myeloid Diseases
NCT03365661Phase 2Withdrawn
- Sponsor
- Masonic Cancer Center
- Start
- Oct 2018
- Primary completion
- Jan 2023
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Masonic Cancer Center. Planned start Oct 2018; status: withdrawn.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03365661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03365661.